Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2022-05-04 00:00:00 ET · period of report 2022-05-02 · accession 0001209191-22-027158 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-04 | 2022-05-02 | SPRY | Odegard Valerie | Pres, CSO | A - Grant | $0.00 | +45.2K | 61.6K | +276% | $0 |
| D | 2022-05-04 | 2022-05-02 | SPRY | Odegard Valerie | Pres, CSO | A - Grant | $0.00 | +90.5K | 90.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-02 | A | A | 45,233 | $0.00 | 61,639 | D | — | — | (F1) The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Derivative | Stock Option (right to buy) | 2022-05-02 | A | A | 90,467 | $0.00 | 90,467 | D | $3.15 · — to 2032-05-01 | 90,467 Common Stock | (F2) The shares subject to the option will vest on May 2, 2023. |